Search
Gilead Sciences to Acquire Biotechnology Company Arcellx
5 day ago /
Read about 0 minute
Author：小编
On February 23, 2026, Gilead Sciences announced that it has reached a definitive agreement with biotechnology company Arcellx to acquire the latter at a price of $115 per share in cash and contingent value rights worth $5 per share, with a total equity value of approximately $7.8 billion. The transaction is expected to be completed in the second quarter of 2026. This acquisition aims to strengthen Gilead's pipeline layout and technology platform in the field of tumor immunotherapy, and to obtain Arcellx's core CAR-T therapy anito-cel and its innovative D-Domain technology platform.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
